Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

4. Drug-Drug Interactions

Patient profiles will be assessed to identify those drug regimens, which may result in clinically significant drug-drug interactions. Drug-drug interactions considered clinically relevant for rifaximin are summarized in Table 2. Only those drug-drug interactions classified as contraindicated clinical significance level 1 or those considered life-threatening which have not yet been classified will be reviewed.

Table 2. Select Rifaximin Drug-Drug Interactions1, 6-8
Interacting DrugInteractionRecommendationClinical Significance Level #
cyclosporineadjunctive use markedly increases systemic rifaximin concentrations, as rifaximin is P-glycoprotein and OATP1B1/3 substrate, and cyclosporine is P-glycoprotein and OATP1B1/3 inhibitorclinical significance of increased exposure unknown; observe for increased adverse effects if combined therapy necessary3-moderate (CP)
eliglustat (Cerdelga®)adjunctive use may increase systemic rifaximin concentrations, as rifaximin is P-glycoprotein substrate, and eliglustat is P-glycoprotein inhibitorclinical significance of increased exposure unknown; observe for increased adverse effects if combined therapy necessary3-moderate (CP)
warfarinconcurrent use may result in changes in INR levels due to an undetermined mechanismmonitor INR values and adjust warfarin doses as needed3-moderate (CP)

Legend:

  • #CP = Clinical Pharmacology
  • INR = international normalized ratio